Related Experiment Videos
Recent advances in systemic therapy for breast cancer
1Johns Hopkins Oncology Center, Baltimore, MD 21287, USA.
Current Opinion in Oncology
|November 18, 1998
Summary
Recent advances in systemic breast cancer therapy show combined chemoendocrine therapy is more effective for early-stage disease. New treatments like paclitaxel and docetaxel demonstrate improved survival and response rates in various breast cancer stages.
Area of Science:
- Oncology
- Medical Therapeutics
Background:
- Systemic therapy is crucial for breast cancer treatment.
- Recent years have seen significant progress in therapeutic options.
Purpose of the Study:
- To review recent advances in systemic therapy for breast cancer.
- To highlight key findings in adjuvant and metastatic treatment strategies.
Main Methods:
- Review of recent clinical trials and therapeutic data.
- Analysis of combined chemoendocrine therapy, chemotherapy regimens, and hormonal therapies.
Main Results:
- Combined chemoendocrine therapy superior to tamoxifen alone in node-negative, estrogen receptor-positive breast cancer.
- Paclitaxel addition to adjuvant AC therapy improves survival in node-positive disease.
- Docetaxel shows superior response rates compared to doxorubicin in metastatic breast cancer.
Conclusions:
- Third-generation aromatase inhibitors are now standard second-line hormonal therapy.
- Anti-HER-2 antibody therapy and novel approaches show promise for breast cancer treatment.